Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
NCT ID: NCT06429345
Last Updated: 2024-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
250 participants
INTERVENTIONAL
2024-06-15
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ameliorating Contrast Induced Nephropathy After Coronary Angiography
NCT06139952
Folic Acid for Prevention of Contrast Induced Nephropathy
NCT02444013
Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy
NCT00939913
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein
NCT00463749
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
NCT03755700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coenzyme Q10 100 Milligrams Oral Capsule
Coenzyme Group received coenzyme Q10 in addition to the the standard preventive measures
Coenzyme Q10 100 Milligrams Oral Capsule
Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
Placebo group
Placebo Group received only the standard preventive measures
Placebo
placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coenzyme Q10 100 Milligrams Oral Capsule
Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
Placebo
placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ST-elevation myocardial infarction (STEMI).
* Non ST-elevation myocardial infarction( NSTEMI).
* Unstable Angina (UA)
Exclusion Criteria
* Preoperative bleeding .
* Intraoperative bleeding or hypotension.
* Patients taking any nephrotoxic medications
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
RAMY Mohamed
Role: PRINCIPAL_INVESTIGATOR
Resident of cardiology department,Ain shams university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams university hospitals
Cairo, , Egypt
Ramy Mohamed Mostafa
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ain shams University
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS70/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.